Lendormin

Brotizolam, the active ingredient in Lendormin, is a benzodiazepine presented as a tablet for oral use. It treats insomnia and other sleep disorders in adults. GNH USA supplies Lendormin as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Brotizolam, a benzodiazepine sedative‑hypnotic, is used for disorders related to sleep regulation. - Insomnia: helps initiate and maintain sleep in adult patients. - Sleep disorder not otherwise specified: improves overall sleep quality. - Transient sleep disturbance: reduces nighttime awakenings.

Adverse reactions may occur with Brotizolam use.

Common Side Effects: - Drowsiness - Dizziness - Headache - Fatigue

Serious or Rare Side Effects: - Respiratory depression - Dependence or withdrawal syndrome - Severe allergic reaction (anaphylaxis)

When prescribing or using Brotizolam, several safety considerations are important. - Use in adults only: limit to patients with diagnosed insomnia. - Avoid abrupt discontinuation: taper under medical supervision. - Caution in hepatic impairment: dose may need adjustment. - Avoid use with other CNS depressants: increased sedation risk. - Pregnancy and lactation: not recommended unless benefits outweigh risks. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Brotizolam can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concomitant use with other benzodiazepines or barbiturates: additive central nervous system depression. - Co‑administration with opioids or alcohol: heightened risk of respiratory depression.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., SSRIs): may increase sedation. - Antihistamines: may enhance drowsiness. - CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma levels of brotizolam.